Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Karim Al-Azizi Added: 2 months ago
SCAI 2025 - Outcomes from prosthesis-patient mismatch (PPM) in patients undergoing transcatheter aortic valve implantation (TAVI) show higher rates of severe predicted and measured PPM in female patients compared to male patients; however, PPM did not affect the five-year survival in women.Dr Karim Al-Azizi (Baylor Scott & White The Heart Hospital, Plano, US) joins us to discuss the incidence and… View more
Author(s): Tanush Gupta Added: 2 weeks ago
New York Valves 25 - Dr Tanush Gupta (UVM Medical Center, Burlington, VT, US) joins us to discuss key conversations around lifetime management for transcatheter aortic valve replacement (TAVR) patients. He discusses key data from the NOTION trial and how this has influenced his practice, as well emerging technologies such as AI simulation models and new valves.Interview Questions:How has FDA… View more
Author(s): Flavio Ribichini , Philipp E Bartko , Stephen Dorman , et al Added: 7 months ago
Moderator Prof Flavio Ribichini (University of Verona, IT) is joined by Dr Hendrik Ruge (German Heart Center Munich, DE), Dr Philipp Bartko (Vienna General Hospital, AT), Dr Stephen Dorman (Bristol Heart Institute, UK) and Dr Nihal Wilde (Bundeswehr Central Hospital, DE), they focus on contemporary lifetime management in transcatheter aortic valve implantation (TAVI).Faculty explore the evolving… View more
Author(s): Flavio Ribichini , Philipp E Bartko , Stephen Dorman , et al Start date: Dec 05, 2024
Moderator Prof Flavio Ribichini (University of Verona, IT) is joined by Dr Hendrik Ruge (German Heart Center Munich, DE), Dr Philipp Bartko (Vienna General Hospital, AT), Dr Stephen Dorman (Bristol Heart Institute, UK) and Dr Nihal Wilde (Bundeswehr Central Hospital, DE) in this one hour webinar focusing on contemporary lifetime management in transcatheter aortic valve implantation (TAVI).Faculty… View more
Author(s): Rayyan Hemetsberger Added: 1 year ago
Dr Rayyan Hemetsberger(Medical University of Vienna, AT) led several patient-level analyses of pooled data from the BIOFLOW-II,-IV and -V trials, comparing the Orsiro DES to the Xience DES. In this interview, he presents the results of his analysis for complex vs. non-complex PCI patients. Further insights on other patient level analysis (calcified lesions, atherothrombotic risk patients) and his… View more
Author(s): David Erlinge Added: 10 months ago
One-year outcomes from INFINITY-SWEDEHEART RCT recently presented at ESC 2024 demonstrated that DynamX Bioadaptor meets primary endpoint and significantly reduces adverse events compared to DES after six months. Dr David Erlinge, the primary investigator of INFINITY-SWEDEHEART RCT, shares a quick summary of the one-year outcomes presented at ESC 2024. He highlights how the novel design and… View more